ADC Development Services Targeting FLT3

As a novel targeted therapy for cancers, antibody-drug conjugates (ADCs) are displaying great potential and promising. Various ADCs against different targets are developed actively in recent years, which need high-quality material such as antibody and linker-payload and optimal conjugation strategy. Creative Biolabs is a leader in the field of antibody production and bio-conjugation for more than ten years, we offer a full range of ADCs design and construction services targeting the specific FLT3 protein, from materials preparation to final product characterization.

Introduction of FLT3

FMS-like tyrosine kinase 3 (FLT3), also known as CD135 (cluster of differentiation antigen 135), is a receptor tyrosine kinase. It is encoded by the FLT3 gene, which is mainly expressed by the immature hematopoietic cells. FLT3 contains five extracellular immunoglobulin-like domains, an extracellular domain, a transmembrane domain, a juxtamembrane domain and a tyrosine-kinase domain. FLT3 plays a critical role in the formation and growth of new blood cells, which also is involved in the normal development of stem cells and the immune system. Mutations of FLT3 can lead to the overexpression of the protein and cause the body to make excess abnormal white blood cells, which then induces some leukemia diseases, such as the acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Therefore, FLT3 is an attractive therapeutic target in the therapy for patients with leukemia.

Schematic illustration of aberrant and potentially druggable signaling in leukemic blasts leading to cellular proliferation and survival advantage in AML. Fig.1 Schematic illustration of aberrant and potentially druggable signaling in leukemic blasts leading to cellular proliferation and survival advantage in AML. (Bohl, 2019)

Anti-FLT3 ADC in Acute Myeloid Leukemia (AML)

FLT3 is a promising marker in the treatment of AML, and effective ADC against it has been designed. AGS62P1 is a novel ADC targeting FLT3, composed of a human anti-FLT3 monoclonal antibody conjugated to a potent cytotoxic drug Auroxime via site-specific conjugation method. Preclinical assessment of the ADC showed that AGS62P1 can be rapidly internalized in AML tumor cell lines and tumor xenografts, which results in significant tumor growth inhibition or complete tumor regression. Moreover, all of the preclinical trial results demonstrated that AGS62P1 has potent antitumor activity against AML tumor and may be an effective and alternative therapeutic option for AML patients.

Structure of AGS62P1. Fig.2 Structure of AGS62P1. (Snyder, 2018)

What Can We Do for You?

ADCs are known to be potent and powerful tumor-killing agents with targeted therapy and minimal side effects for cancer patients. Several effective ADCs have been developed for the AML therapy based on specific targets. With dedicated commitment to the scientific community, Creative Biolabs has perfected our technical pipelines in the development of diverse ADCs. Our featured ADCs services include ADC Antibody Screening, DrugLnk™ Custom Synthesis, Antibody Design and Conjugation, ADC in vitro Analysis and ADC in vivo Analysis. We would like to share our knowledge and passion in this field to promote your ADC development. Please contact us for more information and a detailed quote.


  1. Bohl, S. R.; et al. New targeted agents in acute myeloid leukemia: new Hope on the rise. International journal of molecular sciences. 2019, 20(8): 1983.
  2. Snyder, J. T.; et al. Metabolism of an oxime-linked antibody drug conjugate, AGS62P1, and characterization of its identified metabolite. Molecular pharmaceutics. 2018, 15(6): 2384-2390.

For lab research use only, not for any in vivo human use.

Related Sections

ADC Development for Leukemia: Disease Research:
Online Inquiry
*E-mail Address:
*Products or Services Interested:
Project Description:
*Verification Code:
Verification code
Click image to refresh the verification code.

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.

Contact us
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-357-2254
 Fax: 1-631-207-8356
UK - Germany